Literature DB >> 2495371

Transformation of human cells by oncogenic viruses supports permissiveness for parvovirus H-1 propagation.

S Faisst1, J R Schlehofer, H zur Hausen.   

Abstract

Parvovirus H-1 has been shown to suppress spontaneous and chemically or virally induced tumorigenesis in hamsters. In human cell culture systems propagation of H-1 is restricted to transformed cells, which are killed by H-1 infection, in contrast to normal diploid cells, which are nonpermissive for H-1. By analyzing the permissiveness of a variety of human cells for H-1, it was determined that the majority of tested transformed or immortalized cells which were permissive for H-1 contained the DNA of oncogenic viruses (human papillomavirus, simian virus 40, adenovirus, hepatitis B virus, Epstein-Barr virus, and human T-cell lymphotropic virus type I). Of six transformed cell lines negative for persisting tumor virus DNA, only two were permissive for H-1, while two were semipermissive and two were nonpermissive. Thus, persistence and expression of tumor virus functions appears to promote full permissiveness for H-1 in human cells. However, neither expression of genes of specific viral genomes nor the transformed state of apparently virus-free cells alone was sufficient to render human cells permissive for H-1. Therefore, the effect of tumor virus functions on H-1 in transformed cells seems to be indirect, probably mediated by cellular factors which are induced or switched off during the transformation process. It appears that similar factors are induced or switched off by 5-azacytidine or calcium phosphate, both known inducers of cellular gene expression.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2495371      PMCID: PMC250632     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Multiplication and cytopathogenicity of Simian vacuolating virus 40 in cultures of human tissues.

Authors:  H M SHEIN; J F ENDERS
Journal:  Proc Soc Exp Biol Med       Date:  1962-03

2.  Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma.

Authors:  J Menezes; W Leibold; G Klein; G Clements
Journal:  Biomedicine       Date:  1975-07

3.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

4.  Relationship between potentiation of H-1 growth by human adenovirus 12 and inhibition of the 'helper' adenovirus by H-1.

Authors:  N Ledinko; S Hopkins; H Toolan
Journal:  J Gen Virol       Date:  1969-07       Impact factor: 3.891

5.  A23187: a divalent cation ionophore.

Authors:  P W Reed; H A Lardy
Journal:  J Biol Chem       Date:  1972-11-10       Impact factor: 5.157

6.  Replication process of the parvovirus H-1. I. Kinetics in a parasynchronous cell system.

Authors:  S L Rhode
Journal:  J Virol       Date:  1973-06       Impact factor: 5.103

7.  Growth and cytopathogenicity of H-viruses in human and simian cell cultures.

Authors:  H Toolan; N Ledinko
Journal:  Nature       Date:  1965-11-20       Impact factor: 49.962

8.  Inhibition by H-1 virus of the incidence of tumors produced by adenovirus 12 in hamsters.

Authors:  H W Toolan; N Ledinko
Journal:  Virology       Date:  1968-07       Impact factor: 3.616

9.  Expression of the autonomous parvovirus H1 genome: evidence for a single transcriptional unit and multiple spliced polyadenylated transcripts.

Authors:  M R Green; R M Lebovitz; R G Roeder
Journal:  Cell       Date:  1979-08       Impact factor: 41.582

10.  Inhibition of 7,12-dimethylbenz(a)anthracene-induced tumors in Syrian hamsters by prior infection with H-1 parvovirus.

Authors:  H W Toolan; S L Rhode; J F Gierthy
Journal:  Cancer Res       Date:  1982-07       Impact factor: 12.701

View more
  10 in total

Review 1.  Parvovirus replication.

Authors:  K I Berns
Journal:  Microbiol Rev       Date:  1990-09

2.  Identification of a novel cellular TPR-containing protein, SGT, that interacts with the nonstructural protein NS1 of parvovirus H-1.

Authors:  C Cziepluch; E Kordes; R Poirey; A Grewenig; J Rommelaere; J C Jauniaux
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Susceptibility of human cells to killing by the parvoviruses H-1 and minute virus of mice correlates with viral transcription.

Authors:  J J Cornelis; Y Q Chen; N Spruyt; N Duponchel; S F Cotmore; P Tattersall; J Rommelaere
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

4.  Parvoviruses are inefficient in inducing interferon-beta, tumor necrosis factor-alpha, or interleukin-6 in mammalian cells.

Authors:  J R Schlehofer; M Rentrop; D N Männel
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

5.  Isolation of a fully infectious variant of parvovirus H-1 supplanting the standard strain in human cells.

Authors:  S Faisst; S R Faisst; T Dupressoir; S Plaza; A Pujol; J C Jauniaux; S L Rhode; J Rommelaere
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

6.  Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies.

Authors:  Assia L Angelova; Marc Aprahamian; Ginette Balboni; Henri-Jacques Delecluse; Regina Feederle; Irina Kiprianova; Svitlana P Grekova; Angel S Galabov; Mathias Witzens-Harig; Anthony D Ho; Jean Rommelaere; Zahari Raykov
Journal:  Mol Ther       Date:  2009-04-14       Impact factor: 11.454

7.  NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells.

Authors:  Rauf Bhat; Jean Rommelaere
Journal:  BMC Cancer       Date:  2013-07-31       Impact factor: 4.430

8.  The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers.

Authors:  Assia L Angelova; Mathias Witzens-Harig; Angel S Galabov; Jean Rommelaere
Journal:  Front Oncol       Date:  2017-05-12       Impact factor: 6.244

Review 9.  Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients.

Authors:  Assia L Angelova; Karsten Geletneky; Jürg P F Nüesch; Jean Rommelaere
Journal:  Front Bioeng Biotechnol       Date:  2015-04-22

10.  A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol.

Authors:  Jacek Hajda; Monika Lehmann; Ottheinz Krebs; Meinhard Kieser; Karsten Geletneky; Dirk Jäger; Michael Dahm; Bernard Huber; Tilman Schöning; Oliver Sedlaczek; Albrecht Stenzinger; Niels Halama; Volker Daniel; Barbara Leuchs; Assia Angelova; Jean Rommelaere; Christine E Engeland; Christoph Springfeld; Guy Ungerechts
Journal:  BMC Cancer       Date:  2017-08-29       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.